Myriad Genetics (MYGN) Stock Analysis & Winston Score
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients w
Winston Score: 21/100 — Weak
Weak fundamentals across most pillars.
- Quality: Mixed (8/30)
- Growth: Weak (1/20)
- Cash Flow: Weak (0/10)
- Stability: Mixed (3/10)
- Valuation: Data not available (0/10)
- Ownership: Good (8/15)
